RETRACTED: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference35 articles.
1. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia;Arteaga;J. Clin. Oncol,2001
2. Epidermal growth factor-related peptides and their receptors in human malignancies;Salomon;Crit. Rev. Oncol. Hematol,1995
3. The ErbB receptor family: a therapeutic target for cancer;de Bono;Trends Mol. Med,2002
4. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N. Engl. J. Med,2004
5. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer;Mendelsohn;J. Clin. Oncol,2003
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER;Journal of Pharmacy and Pharmacology;2018-03-25
2. Retraction notice to: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody [Cancer Lett. 357 (2015) 374–383];Cancer Letters;2017-08
3. RETRACTED ARTICLE: Structure-based development and optimization of therapy antibody drugs against TNFα;Amino Acids;2015-03-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3